Amarin announces $100 million cost reduction plan
Ireland-headquartered fish oil-based heart drug specialist Amarin Corporation (Nasdaq: AMRN) yesterday announced important and critical actions including a comprehensive cost and organizational restructuring plan to address current shifts within the company’s US business.
Amarin expects these actions will reduce operating costs by around $100 million over the next 12 months and enable Amarin to maintain a positive contribution margin in the USA while continuing to invest in its imminent European market launches and global expansion for Vascepa/Vazkepa (icosapent ethyl).
The move comes after Amarin posted $94.6 million in first-quarter sales, a 33% plunge from the same period last year, mainly due to loss of US patent protection for its sole drug Vascepa.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze